Melodiol Global Health (STU:1X80) Debt-to-Revenue : 0.40 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Melodiol Global Health Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Melodiol Global Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €5.87 Mil. Melodiol Global Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.05 Mil. Melodiol Global Health's annualized Revenue for the quarter that ended in Dec. 2023 was €14.64 Mil. Melodiol Global Health's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.40.

Melodiol Global Health Debt-to-Revenue Historical Data

The historical data trend for Melodiol Global Health's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Debt-to-Revenue Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.89

1.33

0.77

0.51

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial										-	-	0.76	0.78	0.40

Competitive Comparison of Melodiol Global Health's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melodiol Global Health's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's Debt-to-Revenue falls into.

Melodiol Global Health Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Melodiol Global Health's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.869	+	0.052)	/	11.613
	=	0.51

Melodiol Global Health's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.869	+	0.052)	/	14.64
	=	0.40

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Melodiol Global Health Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (STU:1X80) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (STU:1X80) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

COPHF:USA ME1:Australia

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (STU:1X80) Headlines

No Headlines